S&CO Inc. Buys Shares of 169,791 Boston Scientific Corporation $BSX

S&CO Inc. purchased a new position in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 169,791 shares of the medical equipment provider’s stock, valued at approximately $7,246,000.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after buying an additional 1,436,550 shares in the last quarter. State Street Corp increased its position in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after acquiring an additional 920,495 shares in the last quarter. Capital World Investors increased its position in shares of Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after acquiring an additional 502,627 shares in the last quarter. Norges Bank acquired a new stake in shares of Boston Scientific during the fourth quarter worth $2,199,395,000. Finally, Morgan Stanley lifted its position in Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after acquiring an additional 2,246,308 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: An investment analysis argues that Boston Scientific could recover from its recent headwinds, supporting the view that the company’s diversified portfolio and structural-growth markets can reaccelerate over time. Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
• Positive Sentiment: Analyst consensus remains broadly favorable, with brokerage recommendations suggesting that BSX may merit portfolio consideration. However, the article cautions that sell-side ratings can be overly optimistic and should not be used as the sole investment signal. Brokers Suggest Investing in Boston Scientific
• Neutral Sentiment: Recent fund commentary highlights Boston Scientific’s second-quarter performance and the factors that affected the stock, giving investors additional context on the company’s operating challenges but offering no new company guidance or specific catalyst. Here’s What Hurt Boston Scientific Corporation in Q2
• Negative Sentiment: Parnassus Investments identified a growth slowdown in key Boston Scientific businesses. That raises concerns about near-term revenue momentum and could pressure the stock if weaker growth persists, despite the company’s recent earnings beat and positive longer-term outlook. Boston Scientific Faces Growth Slowdown in Key Businesses

Analysts Set New Price Targets

BSX has been the subject of a number of research analyst reports. Mizuho reduced their target price on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Robert W. Baird set a $56.00 price target on Boston Scientific in a research note on Thursday, July 30th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $60.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Piper Sandler reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a research report on Friday, June 12th. Finally, Barclays decreased their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney purchased 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig bought 5,000 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. The trade was a 19.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 204,322 shares of company stock valued at $9,939,221. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Up 0.1%

Boston Scientific stock opened at $51.77 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company’s 50-day moving average is $46.06 and its 200-day moving average is $59.35. The firm has a market capitalization of $75.02 billion, a PE ratio of 20.96, a P/E/G ratio of 1.13 and a beta of 0.56. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the business posted $0.75 EPS. Boston Scientific’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has authorized a share buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.